In this episode of Biotech 2050, host Rahul Chaturvedi sits down with Nello Mainolfi, Founder, President & CEO of Kymera Therapeutics, to explore his journey from chemist and drug hunter to biotech founder, and the decade-long evolution of Kymera into a leader in targeted protein degradation.
Read MoreAI is reshaping drug discovery, but real breakthroughs need more than powerful models. Rahul Chaturvedi speaks with Nick Myerberg of Braidwell on lessons from AlphaFold, AI drug discovery’s first wave, and how autonomous labs and proprietary data could transform how new medicines are developed.
Read MoreRahul Chaturvedi sits down with Robert Jacks, President & CEO of Sparrow Pharmaceuticals, to discuss leadership, biotech strategy, and his journey from civil engineering to CEO. Discover why building lasting value—not chasing acquisitions—is the key to long-term biotech success.
Read MoreIn this deeply personal and inspiring conversation, Mike Raab, President & Chief Executive Officer of Ardelyx, and Laura Williams, Chief Patient Officer, share how empathy, resilience, and patient advocacy have shaped both their careers and the culture of the company they’ve built.
Read MoreAt the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically rich conversation on leadership, commercialization, and the future of neuropsychiatry.
Read MoreThis episode is proudly sponsored by Quartzy.
At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Connect Biopharma, for a wide-ranging conversation on the future of asthma and COPD treatment.
Read MoreIn this episode of Biotech 2050, recorded during JPM 2026 in San Francisco, host Alok Tayi speaks with Cary Claiborne, CEO of Adial Pharmaceuticals, about a new precision-medicine approach to tackling one of the world’s most widespread and undertreated conditions: alcohol use disorder.
Read MoreThis episode is proudly sponsored by Quartzy.
Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a powerful conversation at the intersection of biotech innovation, leadership, and personal transformation.
Read MoreAt the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could reshape medicine.
Read MoreAt JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and rare-disease drug development.
Read MoreFrom managing a theme park in Canada to leading Boehringer Ingelheim’s U.S. business, Brian Hilberdink’s path is anything but typical. Live from JPM 2026, Alok Tayi explores how frontline sales shaped his leadership across obesity, kidney disease, oncology, and rare disorders.
Read MoreFresh from the JPM 2026 in San Francisco, Alok Tayi welcomes Johan Luthman, Executive Vice President of R&D at Lundbeck, for a sweeping, deeply personal conversation on the future of neuroscience drug development.
Read More
